


Clinical Trial Using UltraInflamX® Medical Food in Rheumatoid Arthritis Patients


The following represents the findings of a recently conducted clinical trial evaluating the health benefits of the Medical Food UltraInflamX. The study was an open-label clinical trial of rheumatoid arthritis patients (n=10) on the UltraInflamX Program, which includes an elimination diet. The study cannot be presented in its entirety at this time because it is pending publication.

Statistically significant decreases in swollen joints and C-reactive protein levels!

62% Decrease in Swollen Joints with the UltraInflamX Program



47% Decrease in C-Reactive Protein Levels with the UltraInflamX Program



Clinical assessment for swollen joints, as determined on 25 joints by a metrologist, showed 21.6 ± 14.1 before beginning the program and 10.6 ± 6.8 at 6 weeks, and 8.3 ± 6.0 ($p=0.002$) at 12 weeks after starting the UltraInflamX Program.

Assessment for serum C-reactive protein showed 41.0 ± 22.6 mmol/L before beginning the program, 23.8 ± 25.2 mmol/L at 6 weeks, and 21.7 ± 18.1 mmol/L ($p=0.019$) at 12 weeks after starting the UltraInflamX Program.

Lewis D. Modification of inflammatory activity in rheumatoid arthritis patients treated with a modified diet and UltraInflamX. Study Site: Department of Medicine and Complementary Medicine Research Unit, Monash University, Australia. Unpublished data.